Table 3. Pharmacokinetic parameters of TMZ and its metabolite AIC after administration of TMZ 75 mg m⁻² per day without (day 7) and with varying doses of Sb (day 21).

	Cohort 1, n=6		Cohort 2, n=6		Cohort 3, n=2
	TMZ	AIC	TMZ	AIC	TMZ	AIC
Cmax (mg l−1), mean±s.d.
TMZ alone (day 7)	6.1±1.7	0.37±0.08	4.1±0.9	0.33±0.09	4.4±1.6	0.40±0.09
TMZ & Sb (day 21)	6.7±3.1	0.32±0.08	3.9±1.2	0.31±0.15	3.6±1.4	0.21±0.25
Ratio (day 21/day 7)	1.02	0.87	0.94	0.76	0.8	0.31
90% CI	0.80–1.31	0.79–0.96	0.71–1.26	0.38–1.50	0.71–0.91	0.001–1.88
AUC(0–24)(mg h l−1), mean±s.d.
TMZ alone (day 7)	11.7±1.9	1.58±0.48	10.8±1.4	1.64±0.31	10.5±0.5	1.70±0.45
TMZ & Sb (day 21)	13.3±2.42	1.70±0.47	11.9±0.96	1.51±0.79	10.3±1.89	n.d.
Ratio (day 21/day 7)	1.14	1.08	1.1	0.73	0.97	n.d.
90% CI	1.04–1.24	1.00–1.18	0.97–1.25	0.35–1.52	0.52–1.81
Tmax(h), median (range)
TMZ alone (day 7)	0.25 (0.25–1.50)	1.75 (1.50–2.00)	0.75 (0.25–1.50)	1.75 (1.50–4.00)	0.63 (0.50–0.75)	2.00 (2.00–2.00)
TMZ & Sb (day 21)	0.50 (0.25–2.00)	2.00 (0.75–3.00)	1.50 (0.25–2.00)	2.00 (1.50–3.00)	0.88 (0.75–1.00)	2.00 (2.00–2.00)
T1/2 (h), mean±s.d.
TMZ alone (day 7)	1.59±0.09	1.71±0.21	1.69±0.08	2.37±0.92	1.78±0.19	2.09±0.26
TMZ & Sb (day 21)	1.71±0.07	1.99±0.11	1.77±0.16	2.56±1.48	1.65±0.02	2.29±0.45

Abbreviations: AUC=area under the curve; C_max=concentration max; n.d=not done; Sb=sorafenib; T_max=time max; TMZ=temozolomide.